These findings translated to an overall sensitivity of 100% (8/8) for p16 loss by immunohistochemistry in detecting CDKN2A biallelic inactivation among higher grade meningiomas, a specificity of 90% (28/31), a negative predictive value of 100% (28/28), and a positive predictive value of 73% (8/11). The gene discussed is CDKN2A; the disease is meningioma.